Use of transplatin to prevent hearing loss

Abstract

Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described.

What is claimed is: 
     
         1 . A method of treating or preventing inflammatory pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of transplatin. 
     
     
         2 . The method of  claim 1 , wherein the method comprises administering the transplatin to the subject before the subject is expected to suffer from inflammatory pain. 
     
     
         3 . The method of  claim 1 , wherein the subject is suffering from inflammatory pain. 
     
     
         4 . The method of  claim 1 , wherein the subject is suffering from an inflammatory pain condition. 
     
     
         5 . The method of  claim 1 , wherein the transplatin is administered via intraperitoneal injection, subcutaneous injection, or intraganglionic injection. 
     
     
         6 . The method of  claim 1 , wherein the transplatin is administered via oral administration. 
     
     
         7 . The method of  claim 2 , wherein the subject is a cancer patient. 
     
     
         8 . The method of  claim 3 , wherein the subject is a cancer patient. 
     
     
         9 . The method of  claim 4 , wherein the inflammatory pain condition is selected from arthritis, cancer, and chronic inflammatory pain. 
     
     
         10 . The method of  claim 1 , wherein the amount of transplatin is between about 0.1 mg/kg and about 50 mg/kg. 
     
     
         11 . The method of  claim 1 , wherein the transplatin is administered with a second anti-inflammatory agent. 
     
     
         12 . The method of  claim 11 , wherein the second anti-inflammatory agent is selected from an NSAID and a combination of NSAIDS. 
     
     
         13 . The method of  claim 11 , wherein the transplatin is administered in a single pharmaceutical composition with the second anti-inflammatory agent. 
     
     
         14 . The method of  claim 11 , wherein the transplatin is administered simultaneously with the second anti-inflammatory agent. 
     
     
         15 . The method of  claim 11 , wherein the transplatin is administered within about 24 hours before administration of the second anti-inflammatory agent. 
     
     
         16 . The method of  claim 11 , wherein the transplatin is administered within about 24 hours after administration of the second anti-inflammatory agent. 
     
     
         17 . The method of  claim 15 , wherein the transplatin is administered within about 1 to about 6 hours before administration of the second anti-inflammatory agent. 
     
     
         18 . The method of  claim 16 , wherein the transplatin is administered within about 1 to about 6 hours after administration of the second anti-inflammatory agent.